Induced Pluripotent Stem Cell (iPSC) Global Market Opportunities And Strategies To 2031

This report describes and explains the induced pluripotent stem cell (iPSC) market and covers 2016-2021, termed the historic period, and 2021-2026 termed the forecast period, along with further forecasts for the period 2026-2031. The report evaluates the market across each region and for the major economies within each region.

The global induced pluripotent stem cell (iPSC) market reached a value of nearly $2,431.2 million in 2021, having increased at a compound annual growth rate (CAGR) of 10.8% since 2016. The market is expected to grow from $2,431.2 million in 2021 to $3,997.5 million in 2026 at a rate of 10.5%. The market is then expected to grow at a CAGR of 9.2% from 2026 and reach $6,195.8 million in 2031.

Growth in the historic period resulted from increased healthcare expenditure, a rise in funding, the development of non-animal alternatives for preclinical drug research, reduced cost for drug discovery and increasing demand for personalized medicine. Factors that negatively affected growth in the historic period were the lack of awareness on induced pluripotent stem cells and inadequate reimbursements.

Going forward, increasing prevalence of chronic diseases, growth in genomic projects, development of iPSC-derived disease models, increasing funding and increasing prevalence of genetic diseases will drive market growth. Factors that could hinder the growth of the induced pluripotent stem cell (iPSC) market in the future include automation of iPSC production, the risk associated with induced pluripotent stem cell treatment, high cost associated with storage, low per capita healthcare expenditure and disruption of medical facilities due to Russia-Ukraine war and the coronavirus pandemic.

The induced pluripotent stem cell (iPSC) market is segmented by derived cell type into hepatocytes, fibroblasts, keratinocytes, amniotic cells, and others. The fibroblasts was the largest segment of the induced pluripotent stem cell (iPSC) market by type, accounting for $728.0 million or 29.9% of the total market in 2021. The others market is expected to be the fastest-growing segment going forward at a CAGR of 12.3%.

The induced pluripotent stem cell (iPSC) market is segmented by application into academic research, drug discovery and toxicity studies, regenerative medicine and cell & gene therapy. The drug discovery and toxicity studies was the largest segment of the induced pluripotent stem cell (iPSC) market by application, accounting for $1,178.3 million or 48.5% of the total market in 2021. The cell & gene therapy market is expected to be the fastest-growing segment going forward at a CAGR of 12.0%.

The induced pluripotent stem cell (iPSC) market is segmented by end-users into hospitals, and research laboratories. The research laboratories market was the largest segment of the induced pluripotent stem cell (iPSC) market by end user, accounting for $1,658.7 million or 68.2% of the total market in 2021. The hospitals market is expected to be the fastest-growing segment going forward at a CAGR of 11.3%.

North America was the largest region in the induced pluripotent stem cell (iPSC) market, accounting for 48.9% of the global market in 2021. It was followed by Western Europe, Asia Pacific and the other regions. Going forward, the fastest growing regions in the induced pluripotent stem cell (iPSC) market will be South America and the Middle East, where growth will be at CAGRs of 35.1% and 33.5% respectively from 2021-2026.

The induced pluripotent stem cell (iPSC) market is highly fragmented, with a large number of players. The top ten competitors in the market made up to 27.50% of the total market in 2021. This is mainly due to the high growth potential of the market that is attracting the new players. FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc) was the largest competitor with 10.46% share of the market, followed by Thermo Fisher Scientific, Inc with 6.43%, Takara Bio, Inc with 3.78%, Lonza Group AG with 2.81%, Astellas Pharma Inc with 1.51%, ViaCyte, Inc with 0.90%, Ncardia with 0.70%, REPROCELL USA, Inc with 0.62%, Japan Tissue Engineering Co., Ltd with 0.24%, and Merck KGaA with 0.05%.

The top opportunities in the induced pluripotent stem cell (iPSC) market by derived cell type will arise in the fibroblasts market, which will gain $456.5 million of global annual sales by 2026. The top opportunities in the induced pluripotent stem cell (iPSC) market by application will arise in the drug discovery & toxicity studies market, which will gain $710.9 million of global annual sales by 2026. The top opportunities in the induced pluripotent stem cell (iPSC) market by end-user will arise in the research laboratories market, which will gain $1,018.1 million of global annual sales by 2026. The induced pluripotent stem cell (iPSC) market size will gain the most in the USA at $253.7 million.

Market-trend-based strategies for the induced pluripotent stem cell (iPSC) market include investing in iPSC’s for treating Parkinson’s disease, focusing on strategic collaborations, investing in developing of iPSC-derived NK cells, focus on research and development, focus on investment in regenerative medicine, focus on advancements in technology transfer and clinical translation and focus on solutions for treating diabetes.

Player-adopted strategies in the induced pluripotent stem cell (iPSC) market include focus on expanding operational capabilities, focus on new product launches, focus on strategic agreements and focus on strategic collaborations and partnerships.

To take advantage of the opportunities, the publisher recommends the induced pluripotent stem cell (iPSC) companies to focus on pluripotent stem cells for treating Parkinson’s disease, focus on development of induced pluripotent stem cell (iPSC)-derived NK cells, focus on induced pluripotent stem cell (iPSC) for cell therapy, focus on use of pluripotent stem cells in treating type 1 diabetes, expand in emerging economies, continue to focus on developed markets, focus on strategic partnerships and collaborations, offer competitive prices, continue to use B2B promotions, continue to participate in events and conferences and target fast-growing applications.